Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Up 15.2% in October

Aprea Therapeutics, Inc. (NASDAQ:APREGet Free Report) was the target of a large growth in short interest during the month of October. As of October 15th, there was short interest totalling 15,200 shares, a growth of 15.2% from the September 30th total of 13,200 shares. Based on an average daily volume of 21,400 shares, the short-interest ratio is currently 0.7 days. Currently, 0.3% of the shares of the stock are short sold.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Aprea Therapeutics in a report on Thursday, October 24th. Wedbush reiterated an “outperform” rating and set a $11.00 price objective on shares of Aprea Therapeutics in a research report on Tuesday, August 13th.

Read Our Latest Analysis on APRE

Insider Buying and Selling at Aprea Therapeutics

In other news, Director Marc Duey bought 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 16th. The shares were bought at an average cost of $4.39 per share, for a total transaction of $131,700.00. Following the completion of the transaction, the director now owns 240,113 shares of the company’s stock, valued at approximately $1,054,096.07. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Aprea Therapeutics news, Director Marc Duey purchased 30,000 shares of Aprea Therapeutics stock in a transaction that occurred on Wednesday, October 16th. The shares were bought at an average price of $4.39 per share, for a total transaction of $131,700.00. Following the completion of the transaction, the director now owns 240,113 shares of the company’s stock, valued at approximately $1,054,096.07. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Bernd R. Seizinger acquired 10,000 shares of the stock in a transaction on Friday, October 11th. The shares were acquired at an average price of $2.68 per share, with a total value of $26,800.00. Following the transaction, the director now directly owns 44,730 shares of the company’s stock, valued at $119,876.40. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 42,290 shares of company stock valued at $165,096 in the last 90 days. Insiders own 12.80% of the company’s stock.

Institutional Investors Weigh In On Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Dimensional Fund Advisors LP acquired a new stake in Aprea Therapeutics, Inc. (NASDAQ:APREFree Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned approximately 0.20% of Aprea Therapeutics at the end of the most recent reporting period. 34.19% of the stock is owned by hedge funds and other institutional investors.

Aprea Therapeutics Trading Down 5.6 %

Shares of APRE opened at $4.01 on Thursday. The firm has a fifty day moving average price of $3.29 and a 200-day moving average price of $4.05. The firm has a market capitalization of $21.78 million, a P/E ratio of -1.32 and a beta of 1.03. Aprea Therapeutics has a 12-month low of $2.15 and a 12-month high of $8.85.

Aprea Therapeutics (NASDAQ:APREGet Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.05. The company had revenue of $0.56 million during the quarter, compared to analysts’ expectations of $0.10 million. Aprea Therapeutics had a negative net margin of 1,012.37% and a negative return on equity of 56.38%. Analysts predict that Aprea Therapeutics will post -2.74 earnings per share for the current year.

About Aprea Therapeutics

(Get Free Report)

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.

See Also

Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.